期刊
MATRIX BIOLOGY
卷 68-69, 期 -, 页码 318-332出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.matbio.2017.12.013
关键词
Renal fibrosis; TGF beta; Pirfenidone; Endothelin-receptor A blockers; Galectin-3; Periostin; DDR1; CB1; miRNA; CKD; Biomarker; Collagen degradation products; Urinary exosomes; Targeted therapy
Renal fibrogenesis is the common final pathway to all renal injuries that consequently leads to Chronic Kidney Disease (CKD). Renal fibrogenesis corresponds to the replacement of renal functional tissue by extra-cellular matrix proteins, mainly collagens, that ultimately impairs kidney function. Blockade of the renin angiotensin system by Angiotensin Converting Enzyme inhibitors (ACEi) or Angiotensin Receptor Blockers (ARBs) was the first strategy that proved efficient to blunt the development of renal fibrogenesis independently of its systemic action on blood pressure. Although this strategy has been published 20 years ago, there is to date no novel therapeutic targets that are both safe and efficient in hindering renal fibrogenesis and CKD in humans, nor there is any new biomarker to precisely quantify this process. In our review, we will focus on the most recent pathways leading to fibrogenesis which have a high therapeutic potential in humans and on the most promising biomarkers of renal fibrosis. (C) 2017 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据